Sangamo Therapeutics Pronounces Transition to Buying and selling on OTCQB Project Marketplace
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq:…
Plus Therapeutics Regains Compliance with Nasdaq Minimal Bid Worth Requirement
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV)…
Lyra Therapeutics, Inc. Proclaims Goal to Voluntarily Record Shape 25 for Delisting from Nasdaq and Next Deregistration with the SEC
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the…
Kailera Therapeutics Proclaims Pricing of Preliminary Public Providing
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq:…
Allogene Therapeutics Broadcasts Proposed Public Providing of $175 Million of Commonplace Inventory
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics,…
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Place with AI-Pushed Tech in Computerized Compliance Area
As regulatory calls for accentuate and manufacturing environments grow to be extra…
Denali Therapeutics Regains Complete Rights to Investigational Treatment DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Denali plans to proceed medical building of DNL593, which is designed to…
Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Begin Section 2/3 Medical Trial of SIL204 in In the community Complex Pancreatic Most cancers
Important regulatory milestone marks development into clinical-stage building of next-generation RNAi remedy…
